Overall Trading Platform
Viatris Inc is a drug manufacturers-specialty & generic business based in the US. Mylan shares (MYL) are listed on the NASDAQ and all prices are listed in US Dollars. Mylan employs 35,000 staff and has a trailing 12-month revenue of around USD$11.5 billion.
We update our data regularly, but information can change between updates. Confirm details with the provider you're interested in before making a decision.
|52-week range||USD$0.077 - USD$19.02|
|50-day moving average||USD$16.4214|
|200-day moving average||USD$16.1173|
|Wall St. target price||USD$21.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.516|
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-05-07)||N/A|
|1 month (2021-04-14)||N/A|
|3 months (2021-02-14)||N/A|
|6 months (2020-11-17)||-100.00%|
|1 year (2020-05-15)||-100.00%|
|2 years (2019-05-17)||-100.00%|
|3 years (2018-05-17)||-100.00%|
|5 years (2016-05-17)||-100.00%|
Valuing Mylan stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mylan's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mylan's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 31x. In other words, Mylan shares trade at around 31x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Mylan's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.59. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Mylan's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Mylan's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$3.5 billion.
The EBITDA is a measure of a Mylan's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$11.5 billion|
|Operating margin TTM||15.72%|
|Gross profit TTM||USD$4.6 billion|
|Return on assets TTM||3.63%|
|Return on equity TTM||0%|
|Market capitalisation||USD$8.6 billion|
TTM: trailing 12 months
There are currently 47.1 million Mylan shares held short by investors – that's known as Mylan's "short interest". This figure is 1.4% up from 46.5 million last month.
There are a few different ways that this level of interest in shorting Mylan shares can be evaluated.
Mylan's "short interest ratio" (SIR) is the quantity of Mylan shares currently shorted divided by the average quantity of Mylan shares traded daily (recently around 4.2 million). Mylan's SIR currently stands at 11.15. In other words for every 100,000 Mylan shares traded daily on the market, roughly 11150 shares are currently held short.
However Mylan's short interest can also be evaluated against the total number of Mylan shares, or, against the total number of tradable Mylan shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Mylan's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 Mylan shares in existence, roughly 90 shares are currently held short) or 0.1105% of the tradable shares (for every 100,000 tradable Mylan shares, roughly 111 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Mylan.
Robinhood is expected to go public, here’s what you need to know if you’re looking to buy in from Singapore.
Steps to owning and managing Roblox stocks, with 24-hour and historical pricing before you buy.
Steps to owning and managing Coinbase shares.
Ever wondered how to buy shares in Blue Apron? We explain how and compare a range of providers that can give you access to many brands, including Blue Apron.
Ever wondered how to buy shares in B&G Foods? We explain how and compare a range of providers that can give you access to many brands, including B&G Foods.
Ever wondered how to buy shares in Kandi? We explain how and compare a range of providers that can give you access to many brands, including Kandi.
Ever wondered how to buy shares in Ayro? We explain how and compare a range of providers that can give you access to many brands, including Ayro.
Ever wondered how to buy shares in The Children’s Place? We explain how and compare a range of providers that can give you access to many brands, including The Children’s Place.
Ever wondered how to buy shares in Tanger Factory Outlet Centers? We explain how and compare a range of providers that can give you access to many brands, including Tanger Factory Outlet Centers.
Ever wondered how to buy shares in Blockbuster? We explain how and compare a range of providers that can give you access to many brands, including Blockbuster.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.